|
|
|
|
Vol. 61, Issue 6, 1340-1347, June 2002
Department of Medicine and Center for Molecular Genetics,
University of California, San Diego, La Jolla, California; and San
Diego Veterans Affairs Healthcare System, San Diego, California
Activation of protein kinase C (PKC) stimulates nicotine-induced
catecholamine secretion. PKC down-regulation by prolonged pretreatment
with phorbol 12-myristate 13-acetate diminished nicotine-induced catecholamine secretion only slightly (~16%), suggesting substantial PKC independence of nicotinic receptor activation. However, we found
that bisindolylmaleimide compounds (which are also putative PKC
chemical inhibitors) dramatically inhibited nicotine-induced catecholamine secretion (IC50 values of ~24-37 nM). This
inhibition was specific for the nicotinic cholinergic receptor.
Catecholamine secretion induced by other nicotinic agonists (such as
epibatidine, anatoxin, or cytisine) was also powerfully antagonized by
bisindolylmaleimide II (IC50 values of ~60-90 nM). Even
high-dose nicotinic agonists failed to overcome the inhibition by
bisindolylmaleimide II, suggesting noncompetitive nicotinic antagonism
by this class of compounds. Nicotinic inhibition by bisindolylmaleimide
seemed not to be readily reversible. Structure-activity studies of
bisindolylmaleimide compounds revealed that bisindolylmaleimides I
through III are the most potent nicotinic antagonists at the nicotinic
cholinergic receptor in PC-12 cells (IC50
37 nM), whereas
bisindolylmaleimide IV and V have far less nicotinic antagonist
activity (IC50 >1 µM); the active compounds I through
III have cationic tails at an indole nitrogen, whereas the least potent
compounds IV and V do not. By contrast, a free NH within the maleimide
ring is crucial for PKC inhibition by this class of compounds. We
conclude that bisindolylmaleimides I through III are some of the most
potent noncompetitive neuronal nicotinic antagonists, indeed the most potent such antagonists we have observed in PC-12 cells.
Nicotinic antagonism of these compounds seems to be independent of PKC inhibition.
This article has been cited by other articles:
![]() |
S. K. Mahata, M. Mahata, G. Wen, W. B. Wong, N. R. Mahapatra, B. A. Hamilton, and D. T. O'Connor The Catecholamine Release-Inhibitory "Catestatin" Fragment of Chromogranin A: Naturally Occurring Human Variants with Different Potencies for Multiple Chromaffin Cell Nicotinic Cholinergic Responses Mol. Pharmacol., November 1, 2004; 66(5): 1180 - 1191. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Huang, Y. Wang, S. B. Cogut, B. S. Mitchell, and L. M. Graves Inhibition of Nucleoside Transport by Protein Kinase Inhibitors J. Pharmacol. Exp. Ther., February 1, 2003; 304(2): 753 - 760. [Abstract] [Full Text] [PDF] |
||||